Low 30-Day Mortality After Atrial Fibrillation Ablation: Results From the Netherlands Heart Registration

Daniel Mol; Michelle D. van der Stoel; Jippe C. Balt; Rohit E. Bhagwandien; Yuri Blaauw; Pascal F.H.M. van Dessel; Vincent J.H.M. van Driel; Antoine H.G. Driessen; Arif Elvan; Rutger J. Hassink; Michiel J.B. Kemme; Karin Kraaier; Wichert J. Kuijt; Justin G.L.M. Luermans; Pepijn H. van der Voort; Sjoerd W. Westra; Joris R. de Groot; Jonas S.S.G. de Jong

doi:10.1016/j.cjca.2022.05.024

Low 30-Day Mortality After Atrial Fibrillation Ablation: Results From the Netherlands Heart Registration

Daniel Mol, Michelle D. van der Stoel, Jippe C. Balt, Rohit E. Bhagwandien, Yuri Blaauw, Pascal F.H.M. van Dessel, Vincent J.H.M. van Driel, Antoine H.G. Driessen, Arif Elvan, Rutger J. Hassink, Michiel J.B. Kemme, Karin Kraaier, Wichert J. Kuijt, Justin G.L.M. Luermans, Pepijn H. van der Voort, Sjoerd W. Westra, Joris R. de Groot, Jonas S.S.G. de Jong

Cardiology

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	1616-1618
Number of pages	3
Journal	Canadian Journal of Cardiology
Volume	38
Issue number	10
Early online date	13 Jun 2022
DOIs	https://doi.org/10.1016/j.cjca.2022.05.024
Publication status	Published - 1 Oct 2022

Bibliographical note

Funding Information:
D. Mol reports speaker/consultancy fee from Abbott. Y. Blaauw is a proctor for Boston Scientific, Abbott, and Medtronic, and received research grants from Medtronic and Atricure . J.G.L.M Luermans reports grants from Biotronik , and a consultancy agreement with Medtronic, outside the submitted work. J.R. de Groot reports research grants to his institution from Atricure , Abbott , Boston Scientific , and Medtronic , personal fees from Atricure, Bayer, Daiichi Sankyo, Servier, Johnson & Johnson, Novartis, and Medtronic, outside the submitted work. J.C. Balt reports consultancy fee to his institution from Abbott. J.S.S.G. de Jong reports consultancy fees from Medtronic and speaker fees from Daiichi-Sankyo and Bayer, outside the submitted work. The remaining authors have no conflicts of interest to disclose.

Funding Information:
Joris R. de Groot and Jonas S.S.G. de Jong contributed equally to this work. None. D. Mol reports speaker/consultancy fee from Abbott. Y. Blaauw is a proctor for Boston Scientific, Abbott, and Medtronic, and received research grants from Medtronic and Atricure. J.G.L.M Luermans reports grants from Biotronik, and a consultancy agreement with Medtronic, outside the submitted work. J.R. de Groot reports research grants to his institution from Atricure, Abbott, Boston Scientific, and Medtronic, personal fees from Atricure, Bayer, Daiichi Sankyo, Servier, Johnson & Johnson, Novartis, and Medtronic, outside the submitted work. J.C. Balt reports consultancy fee to his institution from Abbott. J.S.S.G. de Jong reports consultancy fees from Medtronic and speaker fees from Daiichi-Sankyo and Bayer, outside the submitted work. The remaining authors have no conflicts of interest to disclose.

Access to Document

10.1016/j.cjca.2022.05.024

https://cris.maastrichtuniversity.nl/en/publications/2107aac1-20bd-4d62-89a4-2cfeb0d4b469

Cite this

Mol, D., van der Stoel, M. D., Balt, J. C., Bhagwandien, R. E., Blaauw, Y., van Dessel, P. F. H. M., van Driel, V. J. H. M., Driessen, A. H. G., Elvan, A., Hassink, R. J., Kemme, M. J. B., Kraaier, K., Kuijt, W. J., Luermans, J. G. L. M., van der Voort, P. H., Westra, S. W., de Groot, J. R., & de Jong, J. S. S. G. (2022). Low 30-Day Mortality After Atrial Fibrillation Ablation: Results From the Netherlands Heart Registration. Canadian Journal of Cardiology, 38(10), 1616-1618. https://doi.org/10.1016/j.cjca.2022.05.024

@article{8663fd58f9fe4014af022ac10ae5b27e,

title = "Low 30-Day Mortality After Atrial Fibrillation Ablation: Results From the Netherlands Heart Registration",

author = "Daniel Mol and {van der Stoel}, {Michelle D.} and Balt, {Jippe C.} and Bhagwandien, {Rohit E.} and Yuri Blaauw and {van Dessel}, {Pascal F.H.M.} and {van Driel}, {Vincent J.H.M.} and Driessen, {Antoine H.G.} and Arif Elvan and Hassink, {Rutger J.} and Kemme, {Michiel J.B.} and Karin Kraaier and Kuijt, {Wichert J.} and Luermans, {Justin G.L.M.} and {van der Voort}, {Pepijn H.} and Westra, {Sjoerd W.} and {de Groot}, {Joris R.} and {de Jong}, {Jonas S.S.G.}",

note = "Funding Information: D. Mol reports speaker/consultancy fee from Abbott. Y. Blaauw is a proctor for Boston Scientific, Abbott, and Medtronic, and received research grants from Medtronic and Atricure . J.G.L.M Luermans reports grants from Biotronik , and a consultancy agreement with Medtronic, outside the submitted work. J.R. de Groot reports research grants to his institution from Atricure , Abbott , Boston Scientific , and Medtronic , personal fees from Atricure, Bayer, Daiichi Sankyo, Servier, Johnson & Johnson, Novartis, and Medtronic, outside the submitted work. J.C. Balt reports consultancy fee to his institution from Abbott. J.S.S.G. de Jong reports consultancy fees from Medtronic and speaker fees from Daiichi-Sankyo and Bayer, outside the submitted work. The remaining authors have no conflicts of interest to disclose. Funding Information: Joris R. de Groot and Jonas S.S.G. de Jong contributed equally to this work. None. D. Mol reports speaker/consultancy fee from Abbott. Y. Blaauw is a proctor for Boston Scientific, Abbott, and Medtronic, and received research grants from Medtronic and Atricure. J.G.L.M Luermans reports grants from Biotronik, and a consultancy agreement with Medtronic, outside the submitted work. J.R. de Groot reports research grants to his institution from Atricure, Abbott, Boston Scientific, and Medtronic, personal fees from Atricure, Bayer, Daiichi Sankyo, Servier, Johnson & Johnson, Novartis, and Medtronic, outside the submitted work. J.C. Balt reports consultancy fee to his institution from Abbott. J.S.S.G. de Jong reports consultancy fees from Medtronic and speaker fees from Daiichi-Sankyo and Bayer, outside the submitted work. The remaining authors have no conflicts of interest to disclose.",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/j.cjca.2022.05.024",

language = "English",

volume = "38",

pages = "1616--1618",

journal = "Canadian Journal of Cardiology",

issn = "0828-282X",

publisher = "Elsevier Inc.",

number = "10",

}

Mol, D, van der Stoel, MD, Balt, JC, Bhagwandien, RE, Blaauw, Y, van Dessel, PFHM, van Driel, VJHM, Driessen, AHG, Elvan, A, Hassink, RJ, Kemme, MJB, Kraaier, K, Kuijt, WJ, Luermans, JGLM, van der Voort, PH, Westra, SW, de Groot, JR & de Jong, JSSG 2022, 'Low 30-Day Mortality After Atrial Fibrillation Ablation: Results From the Netherlands Heart Registration', Canadian Journal of Cardiology, vol. 38, no. 10, pp. 1616-1618. https://doi.org/10.1016/j.cjca.2022.05.024

TY - JOUR

T1 - Low 30-Day Mortality After Atrial Fibrillation Ablation

T2 - Results From the Netherlands Heart Registration

AU - Mol, Daniel

AU - van der Stoel, Michelle D.

AU - Balt, Jippe C.

AU - Bhagwandien, Rohit E.

AU - Blaauw, Yuri

AU - van Dessel, Pascal F.H.M.

AU - van Driel, Vincent J.H.M.

AU - Driessen, Antoine H.G.

AU - Elvan, Arif

AU - Hassink, Rutger J.

AU - Kemme, Michiel J.B.

AU - Kraaier, Karin

AU - Kuijt, Wichert J.

AU - Luermans, Justin G.L.M.

AU - van der Voort, Pepijn H.

AU - Westra, Sjoerd W.

AU - de Groot, Joris R.

AU - de Jong, Jonas S.S.G.

N1 - Funding Information: D. Mol reports speaker/consultancy fee from Abbott. Y. Blaauw is a proctor for Boston Scientific, Abbott, and Medtronic, and received research grants from Medtronic and Atricure . J.G.L.M Luermans reports grants from Biotronik , and a consultancy agreement with Medtronic, outside the submitted work. J.R. de Groot reports research grants to his institution from Atricure , Abbott , Boston Scientific , and Medtronic , personal fees from Atricure, Bayer, Daiichi Sankyo, Servier, Johnson & Johnson, Novartis, and Medtronic, outside the submitted work. J.C. Balt reports consultancy fee to his institution from Abbott. J.S.S.G. de Jong reports consultancy fees from Medtronic and speaker fees from Daiichi-Sankyo and Bayer, outside the submitted work. The remaining authors have no conflicts of interest to disclose. Funding Information: Joris R. de Groot and Jonas S.S.G. de Jong contributed equally to this work. None. D. Mol reports speaker/consultancy fee from Abbott. Y. Blaauw is a proctor for Boston Scientific, Abbott, and Medtronic, and received research grants from Medtronic and Atricure. J.G.L.M Luermans reports grants from Biotronik, and a consultancy agreement with Medtronic, outside the submitted work. J.R. de Groot reports research grants to his institution from Atricure, Abbott, Boston Scientific, and Medtronic, personal fees from Atricure, Bayer, Daiichi Sankyo, Servier, Johnson & Johnson, Novartis, and Medtronic, outside the submitted work. J.C. Balt reports consultancy fee to his institution from Abbott. J.S.S.G. de Jong reports consultancy fees from Medtronic and speaker fees from Daiichi-Sankyo and Bayer, outside the submitted work. The remaining authors have no conflicts of interest to disclose.

PY - 2022/10/1

Y1 - 2022/10/1

UR - http://www.scopus.com/inward/record.url?scp=85139109675&partnerID=8YFLogxK

U2 - 10.1016/j.cjca.2022.05.024

DO - 10.1016/j.cjca.2022.05.024

M3 - Article

C2 - 35709933

AN - SCOPUS:85139109675

SN - 0828-282X

VL - 38

SP - 1616

EP - 1618

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

IS - 10

ER -

Low 30-Day Mortality After Atrial Fibrillation Ablation: Results From the Netherlands Heart Registration

Bibliographical note

Access to Document

Other files and links

Cite this